(NASDAQ: INSM) Insmed's forecast annual revenue growth rate of 86.3% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.67%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.46%.
Insmed's revenue in 2026 is $606,423,000.On average, 21 Wall Street analysts forecast INSM's revenue for 2026 to be $350,918,486,688, with the lowest INSM revenue forecast at $204,692,391,480, and the highest INSM revenue forecast at $440,156,971,632. On average, 21 Wall Street analysts forecast INSM's revenue for 2027 to be $582,421,222,992, with the lowest INSM revenue forecast at $409,979,706,192, and the highest INSM revenue forecast at $809,397,369,480.
In 2028, INSM is forecast to generate $845,178,984,216 in revenue, with the lowest revenue forecast at $628,764,880,632 and the highest revenue forecast at $1,052,324,356,272.